University of Lille, CNRS, Centrale Lille, University Polytechnique Hauts-de-France, UMR 8520-IEMN, F-59000 Lille, France.
Biosensors (Basel). 2022 Jul 21;12(7):548. doi: 10.3390/bios12070548.
The ongoing highly contagious Coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), underlines the fundamental position of diagnostic testing in outbreak control by allowing a distinction of the infected from the non-infected people. Diagnosis of COVID-19 remains largely based on reverse transcription PCR (RT-PCR), identifying the genetic material of the virus. Molecular testing approaches have been largely proposed in addition to infectivity testing of patients via sensing the presence of viral particles of SARS-CoV-2 specific structural proteins, such as the spike glycoproteins (S1, S2) and the nucleocapsid (N) protein. While the S1 protein remains the main target for neutralizing antibody treatment upon infection and the focus of vaccine and therapeutic design, it has also become a major target for the development of point-of care testing (POCT) devices. This review will focus on the possibility of surface plasmon resonance (SPR)-based sensing platforms to convert the receptor-binding event of SARS-CoV-2 viral particles into measurable signals. The state-of-the-art SPR-based SARS-CoV-2 sensing devices will be provided, and highlights about the applicability of plasmonic sensors as POCT for virus particle as well as viral protein sensing will be discussed.
正在持续的高传染性 2019 年冠状病毒病（COVID-19）大流行，是由严重急性呼吸系统综合症冠状病毒 2（SARS-CoV-2）引起的，这突显了诊断检测在疫情控制中的基本地位，使感染者与未感染者能够区分开来。COVID-19 的诊断仍然主要基于逆转录聚合酶链反应（RT-PCR），识别病毒的遗传物质。除了通过检测 SARS-CoV-2 特定结构蛋白（如刺突糖蛋白（S1、S2）和核衣壳（N）蛋白）的病毒颗粒的存在来进行患者的感染性测试之外，还提出了许多分子测试方法。虽然 S1 蛋白仍然是感染后中和抗体治疗的主要目标，也是疫苗和治疗设计的重点，但它也已成为即时护理检测（POCT）设备开发的主要目标。这篇综述将重点介绍基于表面等离子体共振（SPR）的传感平台将 SARS-CoV-2 病毒颗粒的受体结合事件转化为可测量信号的可能性。将提供基于 SPR 的 SARS-CoV-2 传感设备的最新进展，并讨论等离子体传感器作为病毒颗粒和病毒蛋白传感的 POCT 的适用性。
